1. Home
  2. DFIN vs SVRA Comparison

DFIN vs SVRA Comparison

Compare DFIN & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Donnelley Financial Solutions Inc.

DFIN

Donnelley Financial Solutions Inc.

HOLD

Current Price

$39.77

Market Cap

991.6M

ML Signal

HOLD

SVRA

Savara Inc.

HOLD

Current Price

$5.40

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFIN
SVRA
Founded
1983
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
991.6M
1.1B
IPO Year
2017
2009

Fundamental Metrics

Financial Performance
Metric
DFIN
SVRA
Price
$39.77
$5.40
Analyst Decision
Strong Buy
Buy
Analyst Count
2
9
Target Price
$61.50
$7.33
AVG Volume (30 Days)
310.8K
1.3M
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.27
N/A
Revenue
$963,000,000.00
N/A
Revenue This Year
$4.98
N/A
Revenue Next Year
$3.87
$430.87
P/E Ratio
$30.46
N/A
Revenue Growth
N/A
N/A
52 Week Low
$37.07
$1.98
52 Week High
$66.25
$7.01

Technical Indicators

Market Signals
Indicator
DFIN
SVRA
Relative Strength Index (RSI) 40.72 56.50
Support Level $37.11 $4.78
Resistance Level $50.68 $5.43
Average True Range (ATR) 1.45 0.26
MACD 0.34 0.04
Stochastic Oscillator 64.37 93.88

Price Performance

Historical Comparison
DFIN
SVRA

About DFIN Donnelley Financial Solutions Inc.

Donnelley Financial Solutions Inc is a risk and compliance software solutions and related services provider. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. It operates in four reportable segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management (its key revenue-generating segment), Investment Companies - Software Solutions, and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States (USA), Europe, Asia, Canada, and Others, of which the USA accounts for the vast majority of its total revenue.

About SVRA Savara Inc.

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Share on Social Networks: